Preventing reperfusion injury in stroke with an acutely dosed NK1R antagonist prodrug (Old ID 27621)
Role
Principal Investigator
Description
Stroke represents a major clinical and societal burden, being a leading cause of adult disability, dementia, and death. The aim is to develop a novel therapeutic approach to significantly improve patient outcomes following an ischaemic stroke through the development of a novel therapeutic agent that can be delivered in conjunction with current approved reperfusion therapy. The plan involves critical de-risking efforts to deliver a low-risk strategy for progression to clinical trial. The plan focuses on the development of prodrugs of the NK1R antagonist, befetupitant, appropriately soluble for i.v. dosing, and accompanied by preclinical PK-PD data for formal, rapid preclinical development.
Date
01 Jan 2022 - 31 Dec 2023
Project Type
GRANT
Keywords
Stroke;Reperfusion Injury;Tachykinin NK1 receptor;Intravenous formulation;NK1 receptor antagonist;Prodrug development
Funding Body
National Health and Medical Research Council (NHMRC)
Amount
20000
Project Team
N/A